Evidence map›Paper›PMID 41362587›Full record

ArticleTherapeutic advances in medical oncology2025

NAB-paclitaxel and cisplatin versus gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.

Qin Wang, Zimeng Wang, Qi Yang, Xiaotong Duan, Lan Peng, Rui You, Youping Liu, Tianliang Xia, Mingyuan Chen, Peiyu Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qin WangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zimeng WangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Qi YangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xiaotong DuanState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Lan PengState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Rui YouNasopharyngeal Carcinoma Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.
Youping LiuNasopharyngeal Carcinoma Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.
Tianliang XiaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Mingyuan ChenNasopharyngeal Carcinoma Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 510060, China.ORCID https://orcid.org/0000-0003-4793-0902
Peiyu HuangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.ORCID https://orcid.org/0000-0001-8635-8609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal induction chemotherapy (IC) regimen for locally advanced nasopharyngeal carcinoma (LA-NPC) remains uncertain. Objectives: The study aims to compare the efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin (NAB-TP) versus gemcitabine plus cisplatin (GP) as IC in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Design: A retrospective analysis. Methods: This study was conducted in LA-NPC patients treated at Sun Yat-sen University Cancer Center between 2012 and 2024. All patients received IC with either the GP or NAB-TP regimen followed by concurrent chemoradiotherapy (CCRT). Propensity score matching (PSM) was used to balance baseline characteristics between the GP and NAB-TP groups. Results: In total, 908 patients with LA-NPC (197 in the NAB-TP group) were enrolled. Before PSM, no statistically significant differences were observed between the NAB-TP and GP group in 5-year overall survival (OS; 98.67% vs 91.67%; Conclusion: IC with the NAB-TP combined with CCRT showed comparable survival efficacy for LA-NPC patients compared with the GP, with reduced acute toxicity.

Indexed as

albumin-bound paclitaxelgemcitabineinduction chemotherapylocoregionally advancednasopharyngeal carcinoma

Identifiers

PMID41362587
PMCPMC12681571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.